Objectives: To assess the in vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents as well as to dissect the genetic basis of fluoroquinolone resistance.
Introduction
The genus Actinobaculum is closely related to the genera Actinomyces, Arcanobacterium and Mobiluncus. 1 These bacteria are curved, non-motile, non-spore-forming Gram-positive bacilli and they are catalase, oxidase and urease negative. 1, 2 They grow preferentially at 378C under strictly anaerobic or microaerophilic conditions. 1 To date, four species have been described (http://www.bacterio.cict.fr/): Actinobaculum schaalii (1997); Actinobaculum suis (1997); Actinobaculum massiliae (2002); and Actinobaculum urinale (2003) . They are probably part of the commensal flora of the human genital or urinary tract. 1 Because of its slow growth and its similarity to normal bacterial flora on skin and mucosa, A. schaalii is difficult to identify by culture and is probably frequently considered as a contaminant. However, A. schaalii has been reported to be responsible for numerous urinary tract infections (UTIs), mainly in elderly patients with underlying urological predispositions. 2 -4 Interestingly, a recent study showed that 22% of 252 urine samples from patients .60 years were positive for A. schaalii using real-time PCR. 3 This microorganism may also cause septic complications such as urosepsis, abscess, osteomyelitis and endocarditis.
2,4 -6 Although A. schaalii is an emerging uropathogen, in vitro susceptibility to antimicrobial agents has been poorly evaluated, particularly in terms of MICs.
Resistance to quinolones is mainly related to the acquisition of point mutations in DNA gyrase (GyrA) and topoisomerase IV (ParC). 7 Alterations predominantly occur in the so-called quinolone-resistance-determining region (QRDR). Note that mutations appear most frequently at positions 83 and 87 in GyrA and 80 and 84 in ParC (Escherichia coli numbering). Since gyrA and parC sequences of A. schaalii are not available, the presence of specific variations in the QRDRs, which might explain fluoroquinolone resistance, has not yet been documented. The aim of this study was to determine the in vitro susceptibility of 48 A. schaalii clinical isolates to 12 antimicrobial agents including those commonly used for the treatment of UTIs. The molecular analysis of fluoroquinolone resistance was also attempted by determining the QRDR sequences of the gyrA and parC genes.
Materials and methods

Bacterial isolates
We examined 48 clinical isolates of A. schaalii recovered from urine (n ¼28), blood (n¼11), abscess (n¼7), biopsy (n¼1) and urethral swab (n ¼1) samples including 10 collected between 2005 and 2008 from Henri Mondor Hospital (Créteil, France), 28 collected between 2004 and 2010 from ADMED (La Chaux-de-Fonds, Switzerland), 8 9 collected between 2000 and 2010 from the University Hospital of Lausanne (Lausanne, Switzerland) and 1 collected in 2010 from Dianalab (Geneva, Switzerland). All 48 strains were accurately identified as A. schaalii by sequencing of the 16S rRNA gene, as previously described. 8 
Antimicrobial susceptibility testing
MICs of the following 12 antibiotics were determined for all strains using the Etest method (bioMérieux, Marcy l'Étoile, France): amoxicillin; ceftriaxone; gentamicin; vancomycin; clindamycin; linezolid; ciprofloxacin; levofloxacin; moxifloxacin; co-trimoxazole; nitrofurantoin; and metronidazole. All tests were performed on freshly poured Schaedler agar supplemented with 5 mg/mL haemin, 1 mg/mL vitamin K1 and 5% sheep blood (lysed sheep blood for co-trimoxazole testing). The plates were inoculated with a bacterial suspension adjusted to a turbidity equivalent to that of a 1 McFarland standard in 0.9% NaCl and incubated anaerobically for 48 h. Bacteroides fragilis ATCC 25285 was used as a quality control strain, and interpretation of results was made according to nonrelated species EUCAST clinical breakpoints (www.eucast.org/), except for co-trimoxazole (Enterobacteriaceae and Staphylococcus spp.), nitrofurantoin (E. coli and Staphylococcus saprophyticus responsible for uncomplicated UTIs) and clindamycin and metronidazole (Gram-positive anaerobes).
PCR amplification and sequencing
Bacterial genomic DNA was extracted using the QIAmp DNA Mini Kit (Qiagen, Courtaboeuf, France). The DNA fragments corresponding to the QRDRs of gyrA and parC genes were first amplified using degenerate primers as previously described. 9 Based on these sequences, a novel pair of specific primers for each gene was specifically designed for A. schaalii: gyrA-As-F2 (5 ′ -CGGAGACCGGCCAGATTC-3 ′ ) and gyrA-As-R2 (5 ′ -GGTGAG GATGGTCGGTTCC-3 ′ ) to give a 316 bp product for gyrA; and parC-As-F2 (5 ′ -AGCGCCGTATTCTCTTCCAG-3 ′ ) and parC-As-R2 (5 ′ -GTCCAGCGAAGAAAT CATCG-3 ′ ) to give a 281 bp product for parC. The PCR mixture (50 mL) contained 1× reaction buffer containing 1.5 mM MgCl 2 , 200 mM of each dNTP, 0.5 mM of each primer, 1.25 U of Taq polymerase (Q-Biogene, Illkirch, France) and 150 ng of DNA template. PCR amplifications were performed using an iCycler thermal cycler (Bio-Rad, Marnes-la-Coquette, France) as follows: (i) an initial denaturation step of 5 min at 958C; (ii) 35 cycles of PCR, with one cycle consisting of 30 s at 958C, 30 s at 558C and 30 s at 728C; and (iii) a final extension step of 10 min at 728C. Purified PCR products were then directly sequenced with the same sets of primers in both directions (GATC Biotech, Konstanz, Germany). The nucleotide sequences were analysed using SeqScape TM v2.0 software (Applied Biosystems, Courtaboeuf, France). Multiple alignment and calculation of amino acid identity was carried out using ClustalX software (version 1.83).
Nucleotide sequence accession numbers
The partial nucleotide sequences of gyrA and parC genes obtained from the A. schaalii HM 883 strain were deposited in the GenBank database under accession numbers HQ009514 and HQ009515, respectively.
Results
Antimicrobial susceptibility
According to EUCAST breakpoints, all isolates were susceptible to amoxicillin, ceftriaxone, gentamicin, vancomycin, linezolid and nitrofurantoin (Table 1 ). All isolates except three (MICs ≥256 mg/L) were highly susceptible to clindamycin ( Table 1 ). All isolates were resistant to ciprofloxacin, whereas 90% and 96% remained susceptible to levofloxacin and moxifloxacin, respectively (Table 1) . A single strain was highly resistant to levofloxacin (MIC ≥32 mg/L) and moxifloxacin (MIC 8 mg/L). Finally, all isolates were resistant to metronidazole (MIC ≥256 mg/L), whereas only 15% were susceptible to co-trimoxazole (Table 1) .
QRDR sequences of gyrA and parC genes
The amino acid sequence of fragments corresponding to the QRDRs of GyrA and ParC was compared with those from other bacterial species (Figure 1 ). All isolates that were susceptible or low-level resistant to levofloxacin/moxifloxacin (n¼47) showed sequences identical to that of the A. schaalii HM 883 isolate (Figure 1) . The GyrA QRDR sequence of A. schaalii presented an amino acid identity with other sequences ranging from 68% to 85%, with the highest identity with Arcanobacterium haemolyticum (85%). The ParC QRDR sequence of A. schaalii presented an amino acid identity with the other sequences ranging from 50% to 88%, with again the highest identity with A. haemolyticum (88%). More specifically, they possessed an alanine (GyrA) or a threonine (ParC) at position 83/80 and an aspartate at position 87/84 (GyrA and ParC, according to E. coli numbering) (Figure 1 ). In contrast, the single isolate exhibiting high-level resistance to levofloxacin and moxifloxacin possessed a unique mutation in GyrA (Ala83Val), whereas no mutation was present in ParC.
Discussion
UTIs are predominantly caused by members of the family Enterobacteriaceae. However, Gram-positive bacteria and polymicrobial infections are not uncommon in patients with underlying urological conditions. A. schaalii is an underestimated opportunistic uropathogen and its search is relevant in cases of unexplained chronic pyuria, especially when there is discrepancy between smear microscopy findings and growth results under aerobic conditions. 2, 4 Although A. schaalii is an emerging uropathogen, particularly in elderly patients, very little information is available about its in vitro 2 In a Danish study describing 76 strains of A. schaalii from 55 patients, all isolates were resistant to trimethoprim and ciprofloxacin, whereas they were susceptible to ampicillin and cefuroxime, and showed varying susceptibility to sulphonamides, but MICs were not provided. 4 In several clinical cases, antimicrobial susceptibility testing has been performed using Etest or disc diffusion methods only for a few antibiotics. An A. schaalii isolate responsible for a vertebral osteomyelitis was susceptible to amoxicillin/ clavulanate (MIC 0.38 mg/L), ceftriaxone (MIC 0.125 mg/L), clindamycin (MIC 0.023 mg/L), rifampin (MIC ,0.002 mg/L), doxycycline (MIC 0.125 mg/L) and vancomycin (MIC 0.25 mg/L). 5 In another clinical case, using the disc diffusion method, the isolate was susceptible to penicillin, amoxicillin, ceftriaxone, tetracycline, clarithromycin, clindamycin, nitrofurantoin and co-trimoxazole, whereas it was resistant to ciprofloxacin. 10 Like related species of Actinomyces, A. schaalii seems to be intrinsically resistant to metronidazole, as expected for a facultative aerobic species.
11
The nature of the mutation (Ala83Val) in the QRDR of the gyrA gene has already been demonstrated to be involved in the development of quinolone resistance in Mycobacterium tuberculosis. 12 Therefore, ParC did not seem to be the primary target of fluoroquinolones in A. schaalii, as opposed to other Gram-positive bacterial species, where mutations conferring quinolone resistance occur preferentially in the parC gene. 7 Interestingly, the strain exhibiting high-level resistance to levofloxacin and moxifloxacin was recovered from a patient who had received moxifloxacin therapy for UTI before isolation of the resistant strain.
For patients with clinically documented UTIs who do not respond to treatment with ciprofloxacin or co-trimoxazole, infection caused by A. schaalii should be suspected, and, if it is the cause of the infection, treatment must be adjusted. Interestingly, one case of chronic pyelonephritis due to A. schaalii has been successfully treated after 6 weeks of clindamycin. 13 Nevertheless, treatment with b-lactams has been successfully used in several cases. 2, 5, 6 However, the optimal duration of antimicrobial drug treatment with b-lactams is not clearly defined even if several weeks of treatment may be required in several cases. 
